PER-012-01未知未知
EFFICACY AND SAFETY OF 200 MCG OR 400 MCG OF MOMETHASONE FUROATE NASAL SPRAY OR PLACEBO IN THE TREATMENT OF ACUTE SINUSITIS EPISODES
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The subjects must have a clinical diagnosis of acute sinusitis, that is, they must have a Total Symptom Score of> 6 and at least one of the following specific symptoms of sinusitis (score> 1): Purulent rhinorrhea lasting at least 7 days before the Randomization Visit but no more than 28 days; Pain / facial pressure or abnormal sensation of touch in the sinuses; Postnasal drip; Headache of sinus origin.
- •The subjects must be at least 12 years of age, belong to any sex or race and weigh> 40 kg.
- •The computed tomography performed at the Screening Visit must show sinusitis before the randomization to the study drug
- •The subjects must be in good health, without any clinically significant disease (other than sinusitis) that could interfere with the procedures or the study schedule, or endanger the safety of the subject.
- •Subjects (and / or their parents / guardians) must give written informed consent. They must be able to comply with the schedules of visits and doses.
- •The serum pregnancy test must be negative at the start.
- •Women should be using a medically accepted method of contraception, ie a double-barrier method, oral contraceptive, Depo-Provera® or Norplant®, before Screening and during the study. Vasectomy and tubal ligation should be considered as unique barrier methods. Women of childbearing age should receive guidance on the appropriate use of contraceptive methods while participating in this study. Women who do not currently have sexual intercourse should agree to use one of the methods mentioned above should they become sexually active during the course of their participation in this study.
- •Subjects must have reported at least one previous episode of acute sinusitis within two years prior to the Screening Visit, but not within four weeks prior to the beginning of the current episode.
排除标准
- •Subjects with computed tomography that does not show sinusitis at the beginning.
- •Subjects with invasive diseases such as meningitis, brain abscesses, orbital cellulitis, osteomyelitis, septicemia or cerebral venous sinus thrombosis.
- •Subjects with other associated complications of sinusitis, which at the investigator´s discretion would place the subject at risk or interfere with the conduct of the study.
- •Subjects in whom sinus or nasal surgery is planned within the next three weeks or in which nasal or sinus surgery was performed within the previous year.
- •Subjects with a history of chronic sinusitis treated with antibiotics for 28 days or longer or current episode of sinusitis lasting more than 28 days.
- •Women of childbearing age who are not using an acceptable contraceptive method.
- •Pregnant women or those who are breastfeeding.
- •Subjects that have used a drug in the research phase in the last 30 days prior to the Selection.
- •Subjects with cystic fibrosis, nasal polyps visible on the physical examination, deviation of the clinically significant nasal septum, Kartagener´s syndrome (immobile lashes) or immunocompromised subjects due to conditions that may interfere with the evaluation of the efficacy or safety of the patient. treatment.
- •Subjects with unstable glaucoma, a history of posterior subcapsular cataract, cardiovascular, pulmonary, renal, hepatic, metabolic, hematologic or neurological clinically significant diseases that, in the opinion of the Investigator, could interfere with the assessment of the safety of the treatment.
- •Subjects with any clinically significant abnormal vital sign at onset or with clinically significant abnormal electrocardiographic findings.
- •Subjects who are allergic to corticosteroids, penicillins, or who are allergic to more than two classes of medications (eg, anaphylactic reaction).
- •Subjects who have not complied with the depuration times of the medication listed in section 3.4.3.2 before randomization.
- •Concurrent need for treatment with another antibiotic other than Augmentin®.
- •Study staff, or subjects directly related to the study staff.
- •Subjects that have been randomized prior to treatment with the study drug.
- •Subjects without full capacity to grant informed consent.
研究者
相似试验
已完成
不适用
EFFICACY AND SAFETY OF 200 MCG OR 400 MCG OF MOMETHASONE FUROATE IN NASAL OR PLACEBO AEROSOL FOR THE TREATMENT OF NASAL POLIES IN SUBJECTS OF 18 YEARS OF AGE IN ADVANCE-J33J33PER-011-01SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
200µg versus 400µg sublingual misoprostol in prevention of postpartum haemorrhagePregnancy and ChildbirthPOSTPARTUM HAEMORRHAGEPACTR201505001107182Dr I.A Ugwu
已完成
4 期
Efficacy and Safety assessment of Miglitol and Metformin SR Fixed dose combination (MIGNAR MF) in patients of Type 2 Diabetes mellitusCTRI/2012/01/002336Glenmark Pharmaceuticals Limited500
招募中
4 期
Type II Diabetic STUDYCTRI/2016/01/006486SV Limited270
招募中
3 期
Comparing the efficacy of a combination of Mometasone and Olopatadine sprays versus Mometasone spray in children with allergic rhinitisIRCT20150426021944N5Oroumia University of Medical Sciences80